Acute and sub-acute dermal toxicity of meloxicam emulgel: Analysis of biochemical, hematological, histopathological and immunohistochemical expression.

Autor: Jyothi VGSS; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India., Veerabomma H; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India., Tryphena KP; Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India., Khatri DK; Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India. Electronic address: dkkhatri10@gmail.com., Singh SB; Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India., Madan J; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India. Electronic address: jitenderpharmacy@gmail.com.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2023 Jun 11; Vol. 660, pp. 88-95. Date of Electronic Publication: 2023 Apr 11.
DOI: 10.1016/j.bbrc.2023.04.001
Abstrakt: Meloxicam, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of osteoarthritis. Despite being more effective against pain mediated by inflammation, it is associated with gastrointestinal, cardiovascular, and renal toxicity. In the current study, acute single-dose (2000 mg/kg) and subacute (500, 1000, and 2000 mg kg -1 for 28 days) dermal toxicity analyses of meloxicam emulgel were conducted in Wistar rats. Various biochemical, hematological, histopathological and immunohistochemical parameters were evaluated. The dermal LD 50 (lethal dose) of meloxicam emulgel was found to be > 2000 mg/kg. No significant adverse effects of meloxicam emulgel following topical administration in subacute toxicity studies were noticed. IL-1β was not expressed post treatment with meloxicam emulgel. IL-1β is an influential pro-inflammatory cytokine that is decisive for host-defence consequence to injury and infection. Therefore, using data gleaned from the extant study, topical administration of meloxicam emulgel may be regarded as safe as the "no observed adverse effect level" (NOAEL) was >2000 mg/kg in experimental animals.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: